The State of the Science in Biotherapeutics Research and Development
Antibody research in response to the COVID-19 pandemic has crash-tested new discovery technologies and caused the industry to find new ways of conducting discovery and development faster and more efficiently. With this as a foundation, the PEGS Engineering
Stream examines the state of the science in biologics R&D, including smarter and higher throughput screening methods, new technologies to accelerate and optimize antibody engineering and the increasing role of machine learning in discovery and
engineering. The Stream also explores developments in therapeutic antibodies for neurodegeneration, autoimmunity, cardiovascular disease and infectious diseases. Plan to join these essential tracks and see why PEGS has become the industry’s
must-attend event in biotherapeutics R&D.
Display of Biologics
Machine Learning Approaches for Protein Engineering